一项基于雇主的新型戒烟药物疗法成本效益分析。

An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation.

作者信息

Jackson Kenneth C, Nahoopii Robert, Said Qayyim, Dirani Riad, Brixner Diana

机构信息

Pharmacotherapy Outcomes Research Center, University of Utah College of Pharmacy, Salt Lake City, UT 84108, USA.

出版信息

J Occup Environ Med. 2007 Apr;49(4):453-60. doi: 10.1097/JOM.0b013e3180459ff2.

DOI:10.1097/JOM.0b013e3180459ff2

PMID:17426529

Abstract

INTRODUCTION

An employer-based cost-benefit analysis for varenicline versus bupropion was conducted using clinical outcomes from a recently published trial.

METHODS

A decision tree model was developed based on the net benefit of treatment to produce a nonsmoker at 1 year. Sensitivity analyses were conducted based on quit rates with placebo and varenicline and the cost of varenicline.

RESULTS

Estimated 12-month employer cost savings per non-smoking employee were $540.60 for varenicline, $269.80 for bupropion SR generic, $150.80 for bupropion SR brand, and $81.80 for placebo. Varenicline was more cost beneficial than placebo, which had quit rates of 16.9% or less. The quit rate with varenicline would have to be <or=16.9% to lose cost benefit over bupropion SR generic.

CONCLUSIONS

The economic benefit of varenicline is improved over bupropion, despite the increased initial cost of varenicline.

摘要

引言

利用最近发表的一项试验的临床结果，对伐尼克兰与安非他酮进行了基于雇主的成本效益分析。

方法

基于治疗产生1年不吸烟者的净效益建立决策树模型。根据安慰剂和伐尼克兰的戒烟率以及伐尼克兰的成本进行敏感性分析。

结果

每位非吸烟员工12个月的雇主成本节约估计为：伐尼克兰540.60美元，安非他酮缓释片仿制药269.80美元，安非他酮缓释片品牌药150.80美元，安慰剂81.80美元。伐尼克兰在成本效益上优于戒烟率为16.9%或更低的安慰剂。伐尼克兰的戒烟率必须≤16.9%，才会在成本效益上不如安非他酮缓释片仿制药。